ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
Immunogen (IMGN) Misses Q3 EPS by 42c
November 3, 2017 6:37 AM EDTImmunogen (NASDAQ: IMGN) reported Q3 EPS of ($0.61), $0.42 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $33.62 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
... More